LANGHORNE, Pennsylvania and OXFORD, England - EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC(R) for the A

read more>>

ST. GALLEN, Switzerland - CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B. Results of the study, which were presented during an oral session at the Gesellscaft

read more>>

VANCOUVER, BRITISH COLUMBIA, - DelMar Pharma today announced that the United States FDA Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerVAL

read more>>

DETROIT, - Henry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma (HGG), a fast growing, brain cancer that often recurs even after surgery, radiation treatment

read more>>

SILVER SPRING, Md. - The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the

read more>>

DURHAM, N.C., - Argos Therapeutics Inc., today announced that it presented a high resolution immune monitoring analysis of AGS-003-006, a Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a

read more>>

Umbilical cord blood stem cells have been successful in the treatment of type 1 diabetes, according to a press release from Cord Blood America IncThe stem cells have been used to re-instruct T cells so that the pancreas will begin producing insulin again, thereby reducing the amount of injected in

read more>>

DUBLIN and RICHMOND, Calif. - The global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other Shir

read more>>

Lyon, France - Alize Pharma II, a drug development company focused on oncology and metabolism and part of the Alize Pharma group, announced today the signing of a licensing agreement with EUSA Pharma for ASPAREC(R), a new L-asparaginase product currently in phase I clinical development for the Pur

read more>>

If your son or daughter has been diagnosed with a type of sarcoma – a tumor in connective tissue like muscles or bones – there are many questions: Will my child make a full recovery? What are the immediate and long-term side effects of treatment Most parents don’t consider whether their ch

read more>>